Melanoma Clinical Trials

Showing 461-480 of 705 trials

Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])

NCT00179764

The purpose of this research study is to evaluate the effectiveness of transplantation of high doses of peripheral blood stem cells (stem cells are special cells found in the blood and bone marrow that produce new blood cells) after treatment with non-myeloablative chemotherapy (not toxic to the bone marrow). In addition, this study will assess the side effects of the transplant.

TumorsMalignant MelanomaHematological Malignancies+2 more

Ann & Robert H Lurie Children's Hospital of Chicago68 participantsStarted Mar 2000

Chicago, Illinois, United States

COMPLETEDPHASE1

Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R

NCT02045368

This phase I dose escalation study will evaluate IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated tumors. 765IGF-MTX is administered as an IV infusion over 1 hour on days 1, 8 and 15 of a 28 day cycle. Treatment continues until disease progression, unacceptable toxicity, or patient refusal. Assessment of response will be confirmed with imaging studies performed at the end of cycle 2 +/- 7 days, and every 2 weeks thereafter.

Breast CancerBrain CancerGastrointestinal Cancers+5 more

IGF Oncology, LLC92 participantsStarted Jan 2014

Chicago, Illinois, United States

Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])

Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R

Related Searches

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)

The Role of Inflammation in Ocular Tumours

Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old

Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Multimodal Spectroscopy (MMS) for in Vivo Noninvasive Assessment of Skin

Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases

Employment and Quality of Life in Patients With Malignant Melanoma

Potential Research Study Participant Registry

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Melanoma Image Analysis Algorithm (MIAA) Validation Study

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

Follow-up of Elderly Patients in Ambulatory Surgery